Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine Jan 28, 2019 7:00am EST
National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology Dec 13, 2018 4:01pm EST
Trevena Promotes Robert T. Yoder to Senior Vice President and Chief Business Officer Dec 10, 2018 7:00am EST
Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring Nov 08, 2018 7:00am EST
Trevena to Present Phase 3, Open-Label Safety Study of Oliceridine at the American Society of Anesthesiologists Annual Meeting Oct 12, 2018 4:01pm EDT
Trevena Stock Trading Halted; FDA Advisory Committee to Review Oliceridine for the Treatment of Moderate to Severe Acute Pain Oct 11, 2018 7:00am EDT
Trevena announces completion of leadership transition and appointment of new director Oct 01, 2018 7:00am EDT
Trevena to Present Oliceridine, a Next Generation IV Opioid for the Management of Moderate to Severe Acute Pain, at FDA Advisory Committee Meeting on October 11, 2018 Sep 10, 2018 4:01pm EDT
